The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 08, 2022
Filed:
Mar. 14, 2022
Applicant:
Ohio State Innovation Foundation, Columbus, OH (US);
Inventors:
Yasuko Rikihisa, Columbus, OH (US);
Wenqing Zhang, Columbus, OH (US);
Assignee:
Ohio State Innovation Foundation, Columbus, OH (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/12 (2006.01); A61K 47/68 (2017.01); A61P 31/04 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/1246 (2013.01); A61K 47/6811 (2017.08); A61K 47/6843 (2017.08); A61P 31/04 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01);
Abstract
Infection with obligatory intracellular bacteria is difficult to treat as intracellular targets and delivery methods of therapeutics are not well-known.translocated factor-1 (Etf-1), a type IV secretion system (T4SS) effector, is a primary virulence factor for an obligatory intracellular bacterium,. Disclosed herein are Etf-1-specific nanobodies (Nbs) that block Etf-1 functions andinfection. Also disclosed is a method for treating human monocytic ehrlichiosis (HME) in a subject with the disclosed nanobodies.